@misc{oai:repo.qst.go.jp:00069560,
 author = {辻, 厚至 and 曽川, 千鶴 and 須藤, 仁美 and 小泉, 満 and 樋野, 興夫 and 原田, 良信 and 佐賀, 恒夫 and 辻 厚至 and 曽川 千鶴 and 須藤 仁美 and 小泉 満 and 原田 良信 and 佐賀 恒夫},
 month = {Oct},
 note = {Malignant pleural mesothelioma (MPM) is a highly aggressive tumor and the prognosis with current treatment remains poor. Thus, development of more effective treatments has been required. Noninvasive imaging is essential for assessment of the efficacy of new treatment. To establish noninvasive imaging for MPM, we compared tumor uptake of three PET tracers, [F-18]-FDG, [F-18]-FLT and [C-11]-thiothymidine. We established subcutaneous and orthotopic models of epithelioid and sarcomatoid MPM in mice, and conducted biodistribution study and PET imaging. Two thymidine analogues, FLT and thiothymidine, highly accumulated in epithelioid MPM, while glucose analogue, FDG, highly accumulated in sarcomatoid MPM.
Then, we measured in vitro cellular uptake of FDG and FLT and the cytosolic thymidine kinase 1 (TK1) activity of each cell line. Uptake of both FDG and FLT in sarcomatoid MPM was higher than that in epithelioid MPM, and the TK1 activity of sarcomatoid was higher than epithelioid MPM, indicating in vitro characters are not always consistent with in vivo behavior. Our results suggest that the suitable PET tracer is different for the evaluation of epithelioid and sarcomatoid MPM., 第67回日本癌学会学術総会},
 title = {悪性中皮腫の非侵襲的画像診断法のためのＰＥＴとレーサーの比較検討},
 year = {2008}
}